Browsing byAuthorOh, Sukjoong

Jump to:
All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
  • Sort by:
  • In order:
  • Results/Page
  • Authors/Record:

Showing results 1 to 6 of 6

Issue DateTitleAuthor(s)Type
2016Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients문영철Article
2015Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial문영철Meeting Abstract
2016Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study문영철Article
2015Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with Radotinib문영철Meeting Abstract
2012Restrospective Multicenter Study Evaluating Efficacy and Safety of Dasatinib and Nilotinib in Patients with Imatinib-Resistant or -intolerant Chronic Myeloid Leukemia in Chronic Phase: Korean CML Working Party성주명Meeting Abstract
2007Velcade (R), thalidomide, dexamethasone (VTD) induction therapy followed by melphalan, prednisone, thalidomide (MPT) maintenance as a first line treatment for the patients (pts) with multiple myeloma (MM) who are non-transplant candidates: Early analysis from the Korean multiple myeloma working party성주명Meeting Abstract

BROWSE